Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label, Study to Evaluate the Safety and Anti-Tumor Activity of FS118, a LAG-3/PD-L1 Bispecific Antibody, as a Monotherapy and in Combination With Paclitaxel, in Patients With Advanced Malignancies

NCT03440437 is registered in ClinicalTrials.gov with invoX Pharma Limited as lead sponsor.

NCT NCT03440437
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03440437 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label, Study to Evaluate the Safety and Anti-Tumor Activity of FS118, a LAG-3/PD-L1 Bispecific Antibody, as a Monotherapy and in Combination With Paclitaxel, in Patients With Advanced Malignancies
Lead sponsor
invoX Pharma Limited
Phase
Phase 1/2
Overall status
Terminated
Start date
April 16, 2018
Completion date
June 21, 2024
Enrollment
80 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, metastatic cancer, squamous cell carcinoma of head and neck